Octanine (Human Coagulation Factor Ix)

The recombinant factor IX supplied by Octanine binds to activated factor X on platelet surfaces, restoring the intrinsic pathway of the coagulation cascade. This enables the conversion of prothrombin to thrombin, leading to fibrin clot formation and normal hemostasis in individuals lacking functional factor IX.

The dose of Octanine is individualized by the prescribing clinician based on the patient’s weight, severity of deficiency, and the clinical situation (e.g., prophylaxis, on‑demand treatment, or surgery). The prescriber determines the exact units or volume to be administered intravenously.

Use of Octanine during pregnancy or lactation should be considered only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians typically evaluate each case, and limited data are available; therefore, it is used under specialist supervision.

To order Octanine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and necessary import documentation.

Octanine provides recombinant human factor IX similar in efficacy to other licensed factor IX concentrates. Compared with plasma‑derived products, recombinant forms have a lower risk of viral transmission and may have different immunogenicity profiles. Choice of product depends on clinical factors, availability, and physician preference.

Octanine must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to the manufacturer’s guidelines.

Octanine is given by intravenous infusion. The healthcare professional prepares the prescribed dose under aseptic conditions and administers it slowly, typically over several minutes, while monitoring the patient for any immediate adverse reactions. Dosing intervals are determined by the treating physician.

The most serious risks include the development of neutralizing antibodies (inhibitors) that reduce efficacy, severe allergic reactions such as anaphylaxis, and rare thrombotic events. Patients should be closely monitored for signs of inhibitor formation and hypersensitivity during and after infusion.

Octanine is contraindicated in individuals with known hypersensitivity to human factor IX or any component of the formulation. Patients with a history of severe inhibitor development or those who have experienced anaphylactic reactions to factor IX products should avoid its use unless under strict specialist supervision.